Inmune Bio (INMB)
NASDAQ:INMB
Want to see INMB full AI Analyst Report?
INMB Stock Chart & Stats
$1.53
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.53
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.09 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)440.58K
Market Cap
$38.55M
Enterprise Value$14.71M
Total Cash (Recent Filing)$21.36M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 05, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding26,585,258
10 Day Avg. Volume255,207
30 Day Avg. Volume440,584
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.76
Price to Sales (P/S)829.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-136.23
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$7.50Price Target Upside390.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory AccelerationFast Track status creates a lasting procedural advantage: more frequent FDA interactions, potential expedited review pathways and design flexibility for an adaptive Phase 2b/3. This materially improves the odds and efficiency of reaching registrational milestones over the next 2–6 months and beyond.
Clinical Target EngagementStatistically significant, core-lab MRI signals of myelin preservation provide durable biological proof-of-concept for XPro’s mechanism. Robust target engagement strengthens trial design credibility, de-risks later-stage registrational plans and supports partnership or payer conversations over the medium term.
Manufacturing & Supply SecuritySecuring a long-term, traceable cord-tissue supply plus initiation of process-validation runs reduces execution risk for CORDStrom. Durable supply agreements and manufacturing progress are essential to meet MAA/MAA-like filing and future commercial scale requirements, improving operational readiness.
Bears Say
Weak Cash GenerationSustained negative operating and free cash flow indicate structural dependence on external capital. With current burn, management expects runway only into Q1 2027, implying likely near-term financing needs that could dilute shareholders or constrain program investment, a durable funding risk.
Pre-Commercial Profitability RiskZero trailing revenue combined with substantial cumulative losses and negative gross profit reflect a classic pre-commercial biotech profile. Until products are approved or partnered, the company lacks sustainable cash generation, leaving long-term viability contingent on successful trials or external funding.
Reduced R&D InvestmentA large, sustained reduction in R&D spend can slow data generation, delay registrational milestones and weaken scientific momentum. While it improves near-term cash flow, prolonged cuts risk undermining trial timelines and partner interest, creating a structural risk to development progress.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.09 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $38.55M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Aug 05, 2026 which is in 45 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on May 07, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.045.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.19.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (390.20% Upside)
$7.50 (390.20% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.97%
12-Months-Change
Fundamentals
Return on Equity
-170.86%
Trailing 12-Months
Asset Growth
-31.70%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful, tangible progress toward a key inflection point: CORDStrom advanced through regulatory planning (PIP approval), manufacturing validation runs began, and a long-term supply agreement was secured — all supportive milestones. XPro imaging work and partnership exploration were also positive. Offsetting these positives are schedule/regulatory timing shifts, a materially limited cash runway (funding through Q1 2027), and a large year-over-year reduction in R&D spend that could indicate slower near-term investment. Overall the call shows constructive execution on regulatory and manufacturing fronts but meaningful financing and execution risks remain.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$7.50
▲(390.20% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.17%
Insiders
4.89% Mutual Funds
1.70% Other Institutional Investors
76.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---